Osaic Holdings
AVTX icon

Osaic Holdings’s Avalo Therapeutics AVTX Stock Holding History

Osaic Holdings’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14 Hold
1
– – ﹤0.01% 7730
2025
Q4 		$18 Sell
1
-1
-50% -$17 ﹤0.01% 7743
2025
Q3 		$18 Hold
2
– – ﹤0.01% 7834
2025
Q2 		$8 Hold
2
– – ﹤0.01% 7697
2025
Q1 		$16 Hold
2
– – ﹤0.01% 7357
2024
Q4 		$14 Hold
2
– – ﹤0.01% 7338
2024
Q3 		$19 Hold
2
– – ﹤0.01% 7340
2024
Q2 		$24 Hold
2
– – ﹤0.01% 7333
2024
Q1 		$43 Buy
2
+1
+100% +$5 ﹤0.01% 7087
2023
Q4 		$9 Hold
1
– – ﹤0.01% 7238
2023
Q3 		$42 Hold
1
– – ﹤0.01% 7283
2023
Q2 		$118 Hold
1
– – ﹤0.01% 7265
2023
Q1 		$584 Buy
+1
New +$788 ﹤0.01% 7095
2022
Q4 		– Hold
0
– – – 7168
2022
Q3 		– Hold
0
– – – 7245
2022
Q2 		– Hold
0
– – – 7326
2022
Q1 		– Hold
0
– – – 7229
2021
Q4 		– Hold
0
– – – 7131
2021
Q3 		– Hold
0
– – – 6972
2021
Q2 		– Hold
0
– – – 6675
2021
Q1 		– Hold
0
– -$1K – 6791
2020
Q4 		– Hold
0
– – – 6171
2020
Q3 		– Hold
0
– – – 6196
2020
Q2 		– Hold
0
– – – 5895
2020
Q1 		– Hold
0
– – – 5795

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Osaic Holdings's AVTX Position: Q1 2026 in Review

Osaic Holdings held its Avalo Therapeutics (AVTX) position steady in Q1 2026 at 1 share worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #7730.

Osaic Holdings first reported a position in AVTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $584 in Q1 2023. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Osaic Holdings held 1 share of Avalo Therapeutics worth $14 as of Q1 2026.
  • Osaic Holdings left its Avalo Therapeutics share count unchanged in Q1 2026.
  • Avalo Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #7730 holding.
  • Osaic Holdings first reported a position in Avalo Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Osaic Holdings's Avalo Therapeutics position peaked at $584 in Q1 2023.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.